Beating Cancer Is Still An Everything-But-Easy Challenge That Pharmaceutical Companies Cannot Solve Overnight
Beating Cancer Is Still An Everything-But-Easy Challenge That Pharmaceutical Companies Cannot Solve Overnight
戰勝癌症仍然是一項極具挑戰的任務，藥品公司無法夜盤即成。
On Tuesday, Merck Group revealed an unexpected decision to end a Phase III trial of its cancer drug Xevinapant. This move threatens to undermine confidence the research abilities of the Darmstadt, Germany-based company that is not related to the U.S-based Merck & Co (NYSE:MRK).
默沙東集團星期二透露了一個出乎意料的決定，結束了其抗癌藥物Xevinapant的III期臨床試驗。這一舉動可能會削弱總部位於德國達姆斯塔特的公司的研究能力信心，該公司與總部位於美國的默克製藥公司（紐交所：MRK）無關。
Merck & Co continues its quest to end cancer.
默克製藥公司繼續致力於終結癌症。
Meanwhile, Merck & Co just reported first-time positive data for its antibody-drug conjugate therapy aimed at lung and breast cancer patients from its open-label Phase II trial.
與此同時，默克製藥公司剛剛公佈了其抗體-藥物聯合治療的陽性Ⅱ期開放試驗針對肺癌和乳腺癌患者的初次數據。
At the beginning of June, Merck also released more good news from its...
6月初，默克製藥公司還發布...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。